Indivior submits NDA for RBP-7000 to treat schizophrenia

In September, Indivior plc (LSE:INDV) submitted an NDA to FDA for RBP-7000 to treat schizophrenia. The product is a once-monthly sustained-release formulation of risperidone using the Atrigel deliver...